肿瘤切除后全股骨置换的并发症发生率及相关因素:日本肌肉骨骼肿瘤学组的发现
本研究回顾性评估了1990年至2020年间在日本12家肿瘤治疗注册机构接受肿瘤切除同期全股骨置换的42例患者,中位年龄47岁、中位随访36.5个月。结果显示髋关节脱位、感染和局部复发常见,外展肌切除和大肿瘤与髋关节脱位正相关,手术切缘阳性与局部复发正相关。作者认为保留外展肌和宽切缘切除肿瘤可预防术后脱位和局部复发。
要点
- 1个月、6个月、1年和2年髋关节脱位率分别为5%、12%、14%和14%。
- 1个月、6个月、1年和2年感染率分别为5%、7%、10%和15%。
- 6个月、1年、2年、5年植入失败率分别为5%(95%CI 1%至15%)、7%(95%CI 2%至18%)、16%(95%CI 6%至29%)、16%(95%CI 6%至29%)。
核心结论
- 在本研究中,接受巨大肿瘤切除和全股骨置换的患者中髋关节脱位、感染和局部复发频繁发生,最终导致再次植入或截肢。
- 保留外展肌和以宽切缘切除肿瘤可预防术后脱位和局部复发。
- 未来研究应关注患者选择标准、髋关节脱位的预防和创新治疗。
研究设计与样本
- 回顾性评估了1990年至2020年间在日本12家专门从事肿瘤治疗的注册机构接受全股骨置换和肿瘤切除(同期同一手术)的42例患者,中位年龄47岁(范围10至79岁)。
- 55%(23例)为男性,79%(33例)为骨肉瘤。
- 中位随访期36.5个月(范围2至327个月)。
- 42例中12%(5例)在2年前失访且未达到研究终点(术后并发症、翻修或截肢),另19%(8例)在2年前死亡但植入物完整,剩余69%(29例)随访至少2年或在最低监测期前达到研究终点。
- 另10%(4例)有至少2年随访但过去5年未就诊。
主要发现
- 1个月、6个月、1年和2年髋关节脱位率分别为5%、12%、14%和14%。
- 1个月、6个月、1年和2年感染率分别为5%、7%、10%和15%。
- 髋关节脱位和感染的多变量分析显示,外展肌切除和大肿瘤尺寸与髋关节脱位正相关。
- 6个月、1年和2年局部复发率分别为5%、15%和15%。
- 6个月、1年、2年和5年植入失败率分别为5%(95%CI 1%至15%)、7%(95%CI 2%至18%)、16%(95%CI 6%至29%)和16%(95%CI 6%至29%)。
临床怎么用
- 作者认为保留外展肌和以宽切缘切除肿瘤可预防术后脱位和局部复发。
- 原文未据此给出其他推荐。
局限性
- 未来研究应关注患者选择标准、髋关节脱位的预防和创新治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing massive tumor resection and total femur replacement (TFR) face a substantial risk of hip dislocation and infection, often resulting in multiple implant revisions or hip disarticulation. These complications can impact their independence and prognosis. Additionally, their shorter life expectancy is influenced by challenges in achieving local radical resection and controlling metastases. Identifying suitable candidates for TFR is vital, necessitating investigations into dislocation, infection, implant failure rates, local recurrence, overall survival, and associated factors. QUESTIONS/PURPOSES: (1) What is the postsurgical complication (hip dislocation and infection) rate and factors associated with postsurgical complications in patients who underwent TFR after tumor resection? (2) What is the local recurrence rate, implant failure rate, overall survival rate, and factors associated with local recurrence and implant failure? METHODS: We retrospectively evaluated 42 patients (median [range] age 47 years [10 to 79 years]) who underwent TFR and tumor resection at the time of the same surgical procedure between 1990 and 2020 at 12 registered institutions that specialized in tumor treatment in Japan. A total of 55% (23) of the patients were men, and 79% (33) had bone sarcoma. The median (range) follow-up period was 36.5 months (2 to 327 months). Of the 42 patients, 12% (5) were lost to follow-up before 2 years without meeting a study endpoint (postsurgical complications, revision, or amputation), and another 19% (8) died before 2 years with implants intact, leaving 69% (29) of the original group who had either follow-up of at least 2 years or met a study endpoint before the minimum surveillance duration. Another 10% (4) had a minimum of 2 years of follow-up but had not been seen in the past 5 years. Infection was defined as deep-seated infection involving soft tissues, bones, joints, and the area around the implant. We did not consider superficial infections. Implant failure was defined when a patient underwent reimplantation or amputation. The complication and implant failure rates were assessed by the cumulative incidence function method, considering competing events. The Kaplan-Meier method was used to estimate the overall survival rate. RESULTS: The 1-month, 6-month, 1-year, and 2-year dislocation rates were 5%, 12%, 14%, and 14%, respectively. The 1-month, 6-month, 1-year, and 2-year infection rates were 5%, 7%, 10%, and 15%, respectively. Multivariable analyses for hip dislocation and infection revealed that resection of the abductor muscles and large tumor size were positively associated with hip dislocation. The 6-month, 1-year, and 2-year local recurrence rates were 5%, 15%, and 15%, respectively. The 6-month, 1-year, 2-year, and 5-year implant failure rates were 5% (95% confidence interval 1% to 15%), 7% (95% CI 2% to 18%), 16% (95% CI 6% to 29%), and 16% (95% CI 6% to 29%), respectively. Multivariable analyses of local recurrence and implant failure that led to reimplantation or amputation revealed that a positive surgical margin was positively associated with local recurrence. The 1-year, 2-year, and 5-year overall patient survival rates were 95% (95% CI 87% to 102%), 77% (95% CI 64% to 91%), and 64% (95% CI 48% to 81%), respectively. CONCLUSION: Hip dislocation, infection, and local recurrence were frequently observed in patients who received massive tumor resection and TFR in our study, eventually leading to reimplantation or amputation. Preserving the abductor muscles and resecting the tumor with a wide margin can prevent postoperative dislocation and local recurrence. Future research should focus on patient selection criteria, prevention of hip dislocation, and innovative treatments. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- Mori T, Kobayashi E, Sato Y, et al. What Are the Complication Rates and Factors Associated With Total Femur Replacement After Tumor Resection? Findings From the Japanese Musculoskeletal Oncology Group. Clin Orthop Relat Res. 2023. PMID: 37796200. doi:10.1097/CORR.0000000000002874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。